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INTRODUCTION
Tenofovir disoproxil fumarate (TDF) is a widely prescribed 
nucleoside analogue reverse transcriptase inhibitor (NRTI) 
for first-line or second-line antiretroviral therapy (ART) for 
HIV-1 infection, even in resource-limited settings.1-4 General-
ly, TDF is used in fixed-dose drug combinations as an NRTI 
backbone with emtricitabine, emtricitabine/efavirenz, em-
tricitabine/ripivirine, or emtricitabine/elvitegravir/cobicistat 
as a once-a-day single-tablet regimen. This development has 
improved conditions of HIV-infected individuals by reducing 
the burden of numerous pills. TDF is relatively well tolerated, 
compared to other antiretroviral drugs,5 although it has sev-
eral distinguishing adverse effects, such as renal toxicity and 
decreased bone mineral density.1,6,7 
Renal damage presenting with clinical features ranging from 
subclinical dysfunction to Fanconi syndrome is a major con-
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cern of long-term use of TDF.6,8,9 TDF accumulates in the cyto-
plasm of proximal renal tubular epithelial cells, inhibiting mi-
tochondrial DNA polymerase and causing dysfunction of the 
oxidative respiratory chain and energy deprivation.6,10,11 This 
acquired renal tubular mitochondriopathy eventually drives ep-
ithelial cells to apoptosis, resulting in proximal tubular dam-
age and renal injury.10-12
The long-term adverse outcomes of antiretroviral drugs or 
their indirect effects are becoming major factors in the deteri-
orating quality of life of HIV-infected individuals in a highly ac-
tive ART era. Therefore, distinguishing clinical or laboratory 
predictors of proximal renal tubular dysfunction (PRTD) with 
regular monitoring of renal function in HIV-infected individu-
als receiving TDF is important for prevention. 
PRTD occurrence rates vary, ranging from 6.3 to 22%, de-
pending on the definitions of PRTD, study populations, study 
design, and observational duration.13-17 Previous studies have 
reported that older age, lower body weight, cumulative exposure 
to TDF, and genetic polymorphisms in the adenosine triphos-
phate-binding cassette gene (ABCC2) encoding multidrug-re-
sistant proteins implicated in TDF efflux are risk factors of PRTD 
in HIV-infected individuals receiving TDF-based ART.13-16 Sev-
eral reports from Japan have shown the importance of low body 
weight and body mass index (BMI) for developing TDF-asso-
ciated renal dysfunction defined as a ≥25% decline in estimat-
ed glomerular filtration rate (eGFR).18-20 However, in studies 
conducted in Europe and North America, body weight or BMI 
was not related to the development of TDF-induced renal in-
sufficiency, as evaluated with decreased eGFR.1,15,17,21,22
This discrepancy according to study population might be 
caused by ethnic differences associated with single-nucleotide 
polymorphisms in genes encoding efflux transporter proteins.22 
It is important to determine the global implications of wheth-
er lower-BMI HIV-infected individuals who receive long-term 
TDF-based ART are at high risk for development of chronic re-
nal disease. If this is indeed true, TDF use will increase, suggest-
ing the need for strict, regular monitoring of renal function, 
which might be hindered in resource-limited settings or patients 
with malnutrition. This study evaluated changes in renal func-
tion and development of PRTD in HIV-infected Koreans receiv-
ing TDF-based ART who have similar body compositions and 
genetics to Japanese and Asian populations, compared to Cau-
casians.
MATERIALS AND METHODS
Study design and participants
We conducted this prospective, longitudinal study over 3 years 
starting in January 2013 in at tertiary care, university-affiliated 
Severance Hospital in Seoul, Republic of Korea. HIV-infected 
Koreans who met the following criteria were eligible: 1) ≥18 
years old and 2) beginning TDF-based ART as first-line therapy 
or antiretroviral drug change to decrease pill burden. We ex-
cluded patients with 1) any acute or chronic opportunistic in-
fections or malignancies treated at enrollment, 2) any concur-
rent medications other than antiretroviral drugs during the 
previous 3 consecutive months before study inclusion, 3) at 
least one ≤60 mL/min/1.73 m2 eGFR using Modification of Diet 
in Renal Disease (MDRD) study equations and serum creati-
nine (SCr) measurement ≥1.2 mg/dL between HIV infection 
and study inclusion, 4) past or current history of diabetes melli-
tus or hypertension, 5) co-infected with hepatitis B virus or hep-
atitis C virus, and 6) at least one irregular visit with ≥6 months 
interval after diagnosis of HIV infection. All participants con-
tinuously received TDF-based ART and regularly visited the 
hospital every 3 months for measurements of renal function 
using blood and urine tests during the 3-year follow-up period. 
A total of 70 HIV-infected Koreans were included, and 50 par-
ticipants finished the study after 20 were lost to follow-up, trans-
ferred to another hospital, or switched from TDF to other NRTIs. 
A retrospective study in the same hospital was conducted 
separately by review of electronic medical records to minimize 
the effects of previous use of other antiretroviral drugs on re-
nal function. The study compared the renal effects of TDF with 
a control group of ART-naïve HIV-infected Koreans. We includ-
ed 40 HIV-infected individuals who received first-line TDF-
based ART for ≥3 years who did not participate in the prospec-
tive study and 24 naïve individuals never exposed to ART over 
≥3 years. All patients were at least 18 years of age, regularly 
visited Severance Hospital every 3 months after HIV diagno-
sis, and received urine and blood tests, including for HIV viral 
load (VL), CD4+ T lymphocyte counts, and SCr every 3 or 6 
months. We applied the exclusion criteria of the prospective 
study to the retrospective study.
This study was approved by the local Ethics Committee of 
the Institutional Review Board. All participants in the prospec-
tive study provided written informed consent. Consent was 
waived for the retrospective study.
Sample and data collection and Measurements 
of NAG and cystatin-C
For the prospective study, plasma and urine were stored imme-
diately at -80°C after collection every 3 months during the first 
year for measurements of plasma cystatin-C and urine N-acetyl-
β-D-glucosaminidase (NAG). We measured phosphate, uric 
acid, creatinine, and β2-microglobulin (β2-MG) by random urine 
tests using an automated urine chemistry analyzer AU5800 
(Beckman Coulter, Fullerton, CA, USA) and LIAISON system 
(DiaSorin, Saluggia, Italy) every 3 months during the first year 
after enrollment. Blood from each participant was analyzed for 
complete blood cell count using a Hematology Analyzer, Advia 
2120 (Siemens Healthcare Diagnostics, Deerfield, IL, USA), 
CD4+ T lymphocyte counts using a flow cytometer (Beckman 
Coulter, Fullerton, CA, USA), HIV VL using a COBAS AMPLICOR 
HIV-1 MONITOR, version 2.42 (Roche Diagnostics, Roche, Ba-
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sel, Switzerland), and SCr, serum uric acid, and serum inor-
ganic phosphate (IP) using an automatic chemistry spectro-
photometric analyzer, Hitachi 7600 (Hitachi, Ltd., Tokyo, Japan) 
every 3 months during the first year and every 6 months dur-
ing the last 2 years.
Urine NAG was measured by kinetic rate assay using N-Assay 
L NAG NITTOBO® [6-methyl-2-phylidil-N-acetyl-1-thio-β-D-
glucosaminide (MPT-NAG)] substrate (Nittobo Medical Co., 
Ltd., Tokyo, Japan) within 1 month of urine collection.13 NAG 
converts MPT-NAG into MPT after dissociation within the urine 
sample. NAG concentration was calculated by measuring the 
rate (ΔE/min) of absorbance increase for MPT at 340 nm. Op-
tical densities as absorbance were measured in an automatic 
chemistry spectrophotometric analyzer (HITACHI 7600, Hita-
chi High-Technologies Corp., Tokyo, Japan). Plasma cystatin-
C was measured by particle-enhanced turbidimetric immuno-
assay using a HITACHI 7600 analyzer (Hitachi High-Technologies 
Corp.).23
BMI was calculated by measuring weight and height at the 
time of enrollment. We collected detailed clinical information 
about drugs and duration of ART. In the retrospective study, the 
age, sex and SCr levels were gathered from electric medical re-
cords.
Definitions
PRTD was defined as meeting at least two of the following crite-
ria: 1) normoglycemic glycosuria (random urine glucose ≥1+ 
with fasting plasma glucose <126 mg/dL), 2) serum uric acid 
<3.5 mg/dL with fractional excretion of uric acid (FEUA) >15%, 
3) urine β2-MG/urine creatinine >0.3 mg/L, 4) fractional excre-
tion of phosphate (FEIP) <82%, and 5) metabolic acidosis (blood 
pH ≤7.34 and serum bicarbonate ≤22 mmol/L).13-16 Hypophos-
phatemia was defined as serum phosphate <2.9 mg/dL. 
The cut-off value for obesity in Korea was defined as 25 kg/m2 
BMI according to Asia-Pacific BMI criteria established by the 
World Health Organization Western Pacific Region and the Ko-
rean Centers for Disease Control and Prevention.24,25
We defined undetectable HIV VL as <20 copies/mL in a plas-
ma quantitative real-time reverse transcription-polymerase 
chain reaction test.
Calculation of renal function and tubular 
abnormalities tests
To evaluate renal function, we used three values of eGFR: the 
MDRD study equations, the Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) equation, and eGFR from cys-
tatin-C. The detailed equations are as follows: 1) eGFR (MDRD)= 
175×(SCr)-1.154×(age)-0.203×(0.742 if female),26 2) eGFR (CKD-EPI)= 
141×minimum (SCr/κ or 1)α×maximum (SCr/κ or 1)-1.209×0.993age× 
(1.018 if female), (κ=0.9 if male, 0.7 if female and α=-0.411 if male, 
-0.329 if female),23 and 3) eGFR (cystatin-C) (Larsson formula)= 
77.239×cystatin C-1.2623.23,27
FEIP and FEUA were calculated with the following equations: 
1) FEIP=(urine phosphate×SCr)/(urine creatinine×plasma phos-
phate)×100 and 2) FEUA=(urine uric acid×SCr)/(urine creatinine× 
plasma uric acid)×100.28
Statistical analysis
Continuous variables were compared using a linear mixed 
model, and categorical data were compared using general es-
timating equations. Post hoc tests were performed on contin-
uous data by paired t-test using Bonferroni correction and on 
categorical data using chi-square analysis and the McNemar 
test. We used the nonparametric Mann Whitney U test to com-
pare continuous variables between groups. All p-values were 
two-tailed, and values ≤0.05 were considered statistically sig-
nificant. All statistical analyses were performed using SPSS 
v.23 (IBM Corp., Armonk, NY, USA) and GraphPad Prism V6 
(GraphPad Software, Inc., La Jolla, CA, USA) software.
RESULTS
The clinical features of participants
All participants in both the prospective and retrospective stud-
Table 1. Clinical Characteristics of Total Participants Enrolled in Prospec-
tive Cohort
Characteristics n=50
Age, yr 44.5±10.8
Gender, male (%) 49 (98)
BMI, kg/m2 23.7±2.70
Time interval between HIV infection and enrollment, month 84 (52–106)
CD4+T lymphocyte, /mm3
0 wk 594.5±233.5
12 wk 598.0±212.1
24 wk 619.5±233.9
48 wk 650.1±222.8
Plasma HIV viral load, <20 copies/mL (%)
00 wk 43 (86)
12 wk 45 (90)
24 wk 46 (92)
48 wk 49 (98)
ART
Total ART duration before enrollment, month 58 (37–85)
TDF use as ART starting regimen (%) 03 (6)
Drug combined with TDF at study period (%)
NNRTIs 22 (44)
PI/r 4 (8)
Unbooted PIs 01 (2)
Integrase inhibitor 22 (44)
PI/r+integrase inhibitor 01 (2)
BMI, body mass index; ART, antiretroviral therapy; TDF, tenofovir; NNRTI, non-
nucleoside reverse transcriptase inhibitor; PI/r, ritonavir-boosted protease in-
hibitor; PI, protease inhibitor.
Data are mean±SD or median (IQR) or number (percent). 
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ies received TDF-based ART with TDF as a co-formulation of 
TDF/FTC. Baseline clinical characteristics of the participants 
in the prospective study are summarized in Table 1. The BMI 
range was 18.5 to 30.3 kg/m2, with 14 (28%) obese patients with 
BMI ≥25 kg/m2. The median weight was 66 kg (range, 51–93 kg). 
In the retrospective study, the median age was 41 [interquartile 
range (IQR) 34–49] years, and the total naïve duration of naïve 
individuals was 58 (IQR 42–69) months. The median BMI was 
23.8 kg/m2, and the percentage of obese individuals was 29.2% 
in ART-naïve individuals; these were 22.5 kg/m2 and 27.5% in 
patients receiving first-line TDF-based ART, respectively.
Change of renal function and parameters for proximal 
tubular dysfunction during 1 year in prospective study
All eGFR values measured as cystatin-C, CKD-EPI, and MDRD 
showed significant changes from 0 to 48 wks (p=0.016 for cys-
tatin, 0.026 for CKD-EPI, and 0.002 for MDRD). The eGFR de-
creased to the lowest level at 12 wks by CKD-EPI and MDRD 
and at 24 wks by cystatin-C. However, eGFR determined using 
all measures increased at 48 wks to a level similar to that at 0 wk. 
SCr levels at 12 wks were significantly higher than at 48 wks 
(0.92±0.19 mg/dL vs. 0.87±0.14 mg/dL, p=0.034 in post hoc test) 
(Table 2). 
FEIP values continuously increased from 9.75±4.64 at 0 wks 
to 12.03±4.63% at 48 wks, a significant change (p=0.020). Log10Uβ2-
MG/Ucr also continuously increased from -2.93±0.33 at 0 wks to 
-2.66±0.67 at 48 wks, a significant change (p=0.013). PTRD inci-
dence increased from 4% at 0 wks to 12% at 48 wks, which was 
not a significant change (p=0.274). Urine NAG level did not dif-
fer according to the four different tests (p=0.969) (Table 2).
A decrease ≥10 mL/min and spontaneous recovery of eGFR 
by cystatin-C were seen for 17 (34%) participants over the 48 wks. 
The lowest eGFR by cystatin-C was at 12 wks in 7 (41.2%) partici-
pants and 24 wks in 10 (17%) (Fig. 1A). A largest continuous de-
crease in eGFR by cystatin-C was 23.35 mL/min, from 93.44 
mL/min at 0 wks to 70.09 mL/min at wks 48 (Fig. 1B). 
Chaining patterns of renal function: 3-years follow-up 
data
In the prospective study, we collected eGFR values calculated 
from SCr levels measured as MDRD and CKD-EPI over 3 years 
to evaluate long-term changes in patterns of renal function. The 
eGFR values for CKD-EPI and MDRD showed a similar ten-
dency to decrease at 12 wks, compared to 0 wks, then increase 
until 48 wks. At 48 wks, eGFR values by CKD-EPI and MDRD 
decreased until 144 wks. SCr levels decreased from 12 to 48 
wks, and then significantly increased until 144 wks. All three 
parameters demonstrated significant changes between 0 and 
144 wks (eGFR by CKD-EPI, p<0.001; eGFR by MDRD, p<0.001; 
SCr, p=0.001) (Fig. 2). 
Comparison of renal functions in first-line TDF-based 
ART and treatment-naïve individuals
We compared changes in renal functions between patients re-
ceiving first-line TDF-based ART without changing antiretrovi-
ral drugs (n=40) and patients not receiving ART (n=24) over 3 
years to evaluate the effects of TDF on renal functions with ex-
clusion of previous antiretroviral drugs. The eGFR measured 
by CKD-EPI in the TDF group declined between 96 and 120 
wks and was significantly lower than that of the naïve group at 
144 wks. The TDF group had significantly lower eGFR by MDRD 
at 12 wks and 144 wks, compared to the naïve group. SCr levels 
were not significantly different between the two groups except 
at 48 wks (Fig. 3).
Table 2. Comparisons of Laboratory Tests Evaluating Renal Function and PRTD for 1 Year in Prospective Cohort (n=50)
Parameters 0 wk 12 wk 24 wk 48 wk p value
eGFR
Cystatin-C, mL/min 90.32±22.53* 89.24±23.77 84.29±18.81* 89.03±18.26 0.016
CKD-EPI, mL/min/1.73 m2 103.04±15.03 98.77±15.47 99.38±16.29 101.50±14.18 0.026
MDRD, mL/min/1.73 m2 98.74±18.85* 92.30±17.23*† 94.56±16.51 97.25±17.99† 0.002
Serum creatinine, mg/dL 000.87±0.16 00.92±0.19* 00.90±0.14 000.87±0.14* 0.012
Nondiabetic glycosuria (%) 1 (2) 1 (2) 1 (2) 2 (4) 0.094
FEIP 9.75±4.64* 10.68±3.25 11.25±5.74 012.03±4.63* 0.020
FEUA 008.25±2.66 07.97±2.87 8.01±3.42 8.81±3.13 0.251
Serum IP, mg/dL 003.32±0.48 03.26±0.53 03.42±0.53 003.37±0.50 0.321
Hypophosphatemia (%) 11 (22) 12 (24) 12 (24) 9 (18) 0.844
Urine β2-MG, µg/mL 000.21±0.20 00.26±0.35 00.45±1.09 000.79±1.74 0.107
Log10Uβ2-MG/Ucr -0-2.93±0.33* --2.88±0.41† 0-2.82±0.63 00-2.66±0.67*† 0.013
PRTD (%) 2 (4) 4 (8) 4 (8) 6 (12) 0.274
Urine NAG, U/L 6.91±6.34 7.03±5.94 6.44±5.89 5.80±3.57 0.969
eGFR, estimated glomerular filtration rate; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; MDRD, Modification of Diet in Renal Disease; FE, frac-
tional excretion; IP, inorganic phosphate; UA, uric acid; β2-MG, β2-microglobulin; PRTD, proximal renal tubular dysfunction; NAG, N-acetyl-β-D-glucosaminidase. 
Data are mean±SD or n (%). 
*†p<0.05 by Post-hoc test using paired t-test with Bonferroni correction. 
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DISCUSSION
In our study, parameters indicating renal function were SCr 
level, eGFR from SCr as MDRD and CKD-EPI, and eGFR from 
plasma cystatin-C. These parameters showed identical pat-
terns of change over the study period. All of the data indicated 
that deteriorating renal function at 12 to 24 wks was ameliorat-
ed at 48 wks. However, after that, all parameters worsened con-
tinuously until 144 wks, although eGFR by cystatin-C was not 
evaluated. The overall trend over 3 years of follow-up showed 
significant deterioration of renal function. We also found, us-
ing retrospective data, that eGFR by SCr at 144 wks was signif-
icantly higher in HIV-infected individuals receiving TDF as 
first-line ART than in ART-naïve individuals. These results sug-
gest that use of TDF could impair renal function in HIV-infect-
ed Koreans after a short time. 
Clinical significant renal impairment was defined as a 10 mL/
min/1.73 m2 decrease in eGFR by MDRD or CKD-EPI at 144 
wks relative to the level at prospective enrollment.20,29 Based 
on this measure, 13 (26%) participants had clinically significant 
renal impairment at 144 wks after TDF use. When we consid-
ered a higher cut-off of 25% from baseline,18 three (6%) partic-
ipants had clinical significant renal impairment at 144 wks. Ac-
cording to CKD stage, 18 (36%) patients in the prospective study 
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had mild CKD (stage 2).30 A considerable number of patients 
had clinically meaningful, mild CKD, with no patients with 
moderate or severe CKD or kidney failure (≥stage 3) CKD in 
this 3-year follow-up study. Our CKD incidence of 2.2–12.4% 
was not low, compared with previous studies in Asian coun-
tries, despite a lack of consistency in definition and inclusion 
population.13,31-34 
An issue related to TDF-induced renal toxicity is whether 
low body weight or BMI might be predictive of toxicity devel-
opment.1,15,18-20,22,35 We did not find any relationship with BMI 
or body weight in further analyses using prospective or retro-
spective data (data not shown). Our results could indicate that 
the influence of low weight or BMI, mainly reported in Japan, 
might not be a problem limited to Asian countries. An impor-
tant global concern is whether HIV-infected individuals with 
lower body weight are at especially high risk of development 
of TDF-induced renal injury. We do not have long-term data for 
≥10 years about this issue. A large, multicenter cohort study and 
meta-analysis are needed to clarify if all HIV-infected individ-
uals, even when living in a resource-limited setting, can receive 
long-term TDF-based co-formulated ART without significant 
renal damage. 
This Korean study has several distinctions and strengths. 
First, we prospectively observed changing patterns in renal 
function using different estimation methods over 3 years. We 
strictly measured laboratory markers for PRTD in urine and 
blood at predefined, fixed times of every 3 months for 1 year. 
Second, we applied GFR values estimated through measure-
ment of plasma cystatin-C to evaluate the effect of TDF use on 
short-term renal function in HIV-infected individuals. Cur-
rently, eGFR by cystatin-C is considered the most precise bio-
marker of creatinine clearance evaluating renal function and 
the most sensitive method that can predict early mild renal 
impairment.23,36 Another advantage of eGFR by cystatin-C is 
that this measurement is not affected by anthropometric vari-
ables of age or sex or by muscle weight, which could differ based 
on race or lifestyle, such as diet, or diseases, such as chronic ex-
hausting infectious diseases, including HIV infection.23,36,37 Also, 
eGFR by cystatin-C is a useful biomarker, especially in proxi-
mal tubular injury, because plasma cystatin-C is initially filtered 
at the glomerulus and reabsorbed by epithelial cells of the 
proximal tubule, with only small amounts excreted into urine.38,39 
These characteristics indicate that eGFR by cystatin-C may be 
a more appropriate biomarker for evaluating PRTD and early 
renal dysfunction in HIV-infected individuals receiving TDF-
backbone ART than eGFR calculated from SCr, such as by MDRD 
or CKD-EPI. However, we must consider that plasma cystatin-
C level might be affected by chronic inflammation from the HIV 
infection or high HIV VL.40 The evaluation of renal function by 
eGFR by cystatin-C in our study might have been minimally af-
fected by inflammation, because almost all participants had 
undetectable HIV VL during the first year. Our unconvention-
al evaluation of eGFR by cystatin-C for short-term changes in 
renal function with TDF showed a significant decrease in re-
nal function at 24 wks, compared to baseline. However, eGFR 
by cystatin-C recovered at 48 wks to baseline levels, although 
this result was insignificant in post hoc tests. In addition, some 
participants showed a continuous decline until 48 wks. There-
fore, further study measuring eGFR by cystatin-C over several 
years is warranted to establish if eGFR by cystatin-C continu-
ously decreases after 48 wks, similar to eGFR from SCr. 
Several new biomarkers for predicting acute renal injury are 
being evaluated for different clinical conditions. Emerging 
biomarkers specific for proximal tubular injury are neutrophil 
gelatinase-associated lipocalin, kidney injury molecule-1, reti-
nol-binding protein, interleukin-1β, and liver fatty acid-binding 
protein.8,41,42 The major pathological finding that TDF-induced 
renal injury is acquired in proximal tubular mitochondriopa-
thy may introduce a new dimension to studies evaluating these 
biomarkers in HIV-infected individuals receiving TDF. Early 
detection of PRTD will be important as use of TDF increases 
as a fixed-dose, co-formulated drug. 
Our data showed that renal function evaluated by different 
tests and equations eventually showed a significant decline at 
3 years from the start of TDF use in both a prospective and a 
retrospective observation. Therefore, clinicians need to careful-
ly consider the development of renal impairment and regularly 
monitor parameters of renal function, especially in HIV-infect-
ed individuals receiving TDF-backbone ART for more than one 
year. With patients taking once-a-day ART with a co-formulat-
ed pill containing mostly TDF, physicians must identify early 
predictive biomarkers or clinical factors to make a prognosis 
of the development of long-term renal dysfunction. They must 
consider changing TDF for HIV-infected individuals showing 
an early decline of renal function within 1 year of TDF use. 
This study had several limitations. First, it was a single-cen-
ter study with a relatively small number of patients. The pre-
dictive risk factors of PRTD and mild CKD could not be ana-
lyzed for confounding variables, because few patients fulfilled 
the criteria for these conditions. The measurement of cystatin-
C was performed in only 1 year of the 3-year follow-up. Never-
theless, our findings might have clinical usefulness as a long-
term observation of HIV-infected Koreans receiving TDF-based 
ART for changing patterns in renal functions using several pa-
rameters. 
In conclusion, we observed that around one-quarter of HIV-
infected Koreans receiving TDF-backbone ART over 3 years 
had clinically meaningful, mild renal injury without a relation-
ship to body weight or BMI. Therefore, physicians should per-
form regular renal function tests during long-term treatment 
with TDF and should consider TDF discontinuance if eGFR de-
cline develops. 
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